Item 2.02 Results of Operations and Financial Condition.
The Company primarily derives its product revenues from the sale of DEXTENZA® in
The estimated unit sales discussed above are based on preliminary information and management's estimates as of the date of this Current Report on Form 8-K and are subject to completion of the Company's customary closing procedures. The Company's independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, the estimated figures.
The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall be deemed to be "furnished" and not "filed" under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be deemed to be incorporated by reference in applicable filings under the Securities Act of 1933, as amended, or the Exchange Act except as expressly set forth by specific reference in such a filing.
Item 7.01 Regulation FD Disclosure.
The information set forth in or incorporated by reference into Item 2.02 of this Current Report on Form 8-K is incorporated by reference into this Item 7.01.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits: 99.1Ocular Therapeutix, Inc. slide presentation, datedJanuary 2021 Cover Page Interactive Data File (embedded within the Inline XBRL 104 document)
© Edgar Online, source